Tumor promoters are nonmutagenic chemicals that increase the probability of cancer by accelerating the clonal expansion of cells transformed during tumor initiation. The molecular mechanisms underlying this process are only partly understood but interference with signaling pathways regulating cell division and/or cell death is likely to be important. Ras-and β-Catenin-dependent signaling is important for both of these processes and ras and β-catenin genes are known mutational targets in mouse hepatocarcinogenesis. About 80% of liver tumors generated in mice by a promotional regimen including phenobarbital (PB) as tumor promoter and N -nitrosodiethylamine (DEN) as initiator showed β-catenin mutations whereas Ha-ras mutations were not detected. By contrast, tumors from mice treated with DEN alone showed a ∼30% Ha-ras mutation prevalence but no β-catenin mutations. This result suggests that PB-mediated promotion in mouse liver consists in a positive selection for hepatocytes harboring mutations in β-catenin. The gap junction protein connexin 32 (Cx32) was also found to be involved in tumor promotion by PB because Cx32 gene knockout mice were almost entirely resistent to the promotional effects of the barbiturate. The link between β-catenin-signaling and Cx32-dependent gap junctional intercellular communication, if existent, remains obscure.
INTRODUCTION
Primary liver cancer (HCC) is among the 10 most important human cancers worldwide (17) . Its frequency distribution, however, varies considerably between different geographical areas in the world. In certain areas of high risk in southern Africa and southern China, where both hepatitis B virus and aflatoxins are suspect etiological risk factors, HCC is the most frequent cause of cancer death. Most populations from industrialized countries, however, show a comparatively low incidence of HCC, suggesting that the frequency of 'spontaneous' occurrence of this particular cancer in humans is rather low. This contrasts the situation in rodents, in particular in certain strains of mice, where a very high background incidence of 'spontaneously' occurring liver tumours is observed (7, 9) . Notably, these same strains, for example C3H/He mice, are also highly susceptible to chemically induced hepatocarcinogenesis. Among the chemicals that cause an increase in liver tumors when administered at sufficiently high doses to susceptible mice, there are many agents which are generally classified as tumor promoters. These chemicals lack direct genotoxic potential and are assumed to act via specific cellular receptors. For a variety of liver-specific tumor promoters such cellular receptors have been identified that often represent ligand-activated transcription factors. Because many tumor promoters may be of relevance for humans, there is toxicological concern as to whether these xenobiotics should be considered as weak carcinogens or, alternatively, as 'pure' tumor promoters that merely accelerate the outgrowth of preexisting initiated cells in the highly susceptible mouse strains.
Species-and strain-specific differences in susceptibility to hepatocarcinogenesis point towards differences in the molec-ular pathways governing the process of tumor formation. The analysis of tumor-specific mutational alterations of cancerrelated genes may provide very valuable clues to identify such differences, given that genetic alterations are rate-limiting and driving the carcinogenic process. Species and strain differences in the prevalence of mutations in certain cancerrelated genes such as Ha-ras or p53 have been repeatedly demonstrated (3, for a review see 14, 19) . More recently, β-catenin has been implicated in both human and rodent hepatocarcinogenesis (5, 6) . β-catenin codes for a protein associated with E-cadherin, a component of the adherens junction; it is also essential in the Wnt/Wingless signaling pathway mediating nuclear responses to Wnt signals by interacting with T-cell factor transcription factors (18) . Mutation of the conserved serin/threonin residues at the NH 2 -terminal region of β-catenin abolishes conserved glycogen synthase kinase 3β (GSK-3β) phosphorylation sites relevant for β-catenin degradation thus leading to oncogenic activation of the protein (18) .
In addition to alterations in proteins involved in signal transduction pathways, connexins have been identified as important determinants of tumorigenesis in liver and other organs (for a review see 22, 24) . The role of these latter proteins during hepatocarcinogenesis is discussed first.
Role of Connexin32 During Phenobarbital-Mediated Tumor Promotion
Connexins are subunits of gap junctional channels, through which directly neighbouring cells exchange low molecular weight molecules such as ions, second messengers, and cellular metabolites. Intercellular communication mediated via gap junctions (GJIC) plays an important role in tissue homeostasis and in cancer (for a recent review see 22, 24) . Gap junctional proteins are often decreased in tumor tissue and targeted disruption of the connexin32 (Cx32) gene in mice is associated with enhanced occurrence of chemically induced liver tumors (15, 21) . Introduction of activated oncogenes into cells blocks GJIC and similar effects were seen upon exposure of cells to tumor promoting agents (for review 99 0192-6233/03$3.00+$0.00 100 SCHWARZ ET AL TOXICOLOGIC PATHOLOGY see 4, 20, 24) . Hepatocytes express Cx32 and Cx26 and we have recently studied the role of Cx32 for tumor promotion by PB in mouse liver (16) . In this study, liver tumors were induced in 6 weeks old male Cx32-wild-type and Cx32-null mice by sequential treatment with DEN (as initiator) and phenobarbital (as model tumor promoter) according to a "classical initiation-promotion" protocol [for details, see (16) ]. Mice received a single injection of DEN (90 µg/g body wt) and were subsequently kept on phenobarbital-(0.05%) containing or control diet for 39 weeks. The results of this study demonstrated a significant difference in carcinogenic response between Cx32-null and Cx32-wild-type mice: while PB effectively promoted liver tumor development in DEN-initiated Cx32-wild-type mice, the respective gene-knockout mice were almost entirely resistent to promotion by the barbiturate. The majority of liver tumors from Cx32 wild-type mice not treated with PB showed unchanged or even slightly increased Cx32 levels, while the immunohistochemical staining reaction was decreased or totally absent in ∼80% of tumors from PB treated mice (16) . This suggests that PB negatively affects GJIC, a well-known effect of many tumor promoters (4, 20, 24) . Taken together these results demonstrate that Cx32 represents an essential target for promotion of hepatocarcinogenesis by PB.
Action of Liver Tumor Promoters: Role of β-Catenin
Activation of Ha-ras or β-catenin appear to provide transformed mouse hepatocytes with a selective advantage leading to their clonal expansion. Tumor promoters may modulate this process in that they enhance the clonal outgrowth of hepatocytes mutated during tumor initiation. In order to get some insight into the molecular mechanism relevant for tumor promotion by these agents we have addressed the question whether Ha-ras and β-catenin-mutated hepatocytes respond equally to the proliferative stimulus of tumor promoters and-if not, what this might tell us about the mechanism driving positive selection. For this purpose, liver tumors from Cx32-wild-type mice of the study described previously were analyzed for the presence of mutations in Ha-ras and β-catenin, respectively (1) . Mutations at Ha-ras codon 61 were screened by allele-specific oligonucleotide hybridisation, and β-catenin mutations were detected by direct sequencing of PCR products spanning exon 2. The details of this analysis have been reported elsewhere (1) . A summary of the results is presented in Table 1 . Highly significant differences in the prevalence of mutations in the 2 genes were observed between treatment groups. In animals treated with DEN only, ∼30% of tumors showed base substitutions in Ha-ras codon 61, yet none of the tumors from mice treated with DEN followed by PB harbored Ha-ras mutations. An inverse relationship was observed with respect to β-catenin mutations: although no aberrations were detectable in any of 13 tumors analyzed from mice treated with DEN alone, ∼80% of tumors from mice treated sequentially with DEN and PB had β-catenin exon 2 mutations. The highly significant differences in the prevalence of Ha-ras and β-catenin mutations in liver tumors from mice treated with or without PB as a tumor promoter suggest that the barbiturate, which lacks mutational activity by itself, positively selected for β-catenin-mutated hepatoma cells during the promotional phase of carcinogenesis, while it appeared to suppress the growth of cells harboring mutations in Ha-ras ( Figure 1) .
The mechanism underlying positive selection for β-catenin-mutated mouse hepatocytes during promotion by PB is unclear. Mutation of β-catenin has been shown to result in stabilisation and nuclear translocation of the protein, resulting in transcriptional activation of β-catenin/TCF target genes such as cyclin D1 and c-myc (18) . However, neither of these 2 genes differed in expression between β-catenin-mutated and wild-type mouse liver tumors nor was there any indication for nuclear translocation of β-catenin in β-catenin-mutated tumors (1). By contrast, we have very recently observed a selective increase in expression of the enzyme glutamine synthetase in β-catenin-mutated mouse liver tumors (13) . Glutamine synthetase-positive liver lesions have been demonstrated to possess a certain growth advantage as a consequence of their independence from the supply of glutamine (8) that is, for example, required for biosynthesis of purin and pyrimidine nucleobases. Hypothetically, a scenario then could be envisaged in which PB stimulates β-catenindegradation in nonmutated cells, eg, by activating GSK-3β, while β-catenin-mutated cells would be rescued from this type of repression by the barbiturate resulting in increased glutamine concentrations by transcriptional activation of glutamine synthetase.
Nuclear events could also play a role: exposure of hepatocytes to PB induces a pleiotropic transcriptional response that is, at least partly, mediated by activation of the constitutive androstane receptor (CAR). PB induces nuclear translocation of CAR, which then binds together with retinoic acid X receptor (RXR) as heterodimeric transcription factor to CAR response elements in PB-responsive genes (for a review see 10) . Cross-talk between CAR/RXR and β-catenin/TCF may well exist in analogy to that seen with other nuclear receptors (11) .
To test this hypothesis, we have analyzed the effect of PB on the activity of a β-catenin/TCF-responsive luciferase reporter (commonly known as topflash; 12). Cells from 3 different hepatoma lines were used for this analysis, originating from rat (FTO-2B and MH1C1) and mouse (55.1c) liver tumors. The cells were first screened for the presence of β-catenin mutations: although no mutation was detected in cells of line MH1C1, FTO-2B demonstrated a base substitution in codon 33 in one of the two β-catenin alleles while 55.1c cells showed a heterozygous deletion in the NH 2 -terminal part of the gene. Cells of all 3 lines were transiently transfected with the topflash-reporter driving the firefly luciferase together with the renilla luciferase-reporter pRL-CMV (used for normalization). The results of the analysis are shown in Figure 2 : incubation of 55.1c and MH1C1 cells with PB resulted in an about 20% reduction in reporter activity. By contrast, a slight increase in reporter activity was seen in PB-exposed FTO-2B cells. The values shown in Figure 2A were normalized for all 3 cell types to the respective non-PB-treated controls. In absolute values (arbitrary units), the basal activity of the reporter was about 10-20 times higher FIGURE 2.-Effect of phenobarbital on the activity of a β-catenin/TCF-driven luciferase reporter (topflash). A) PB (1.5 mM) led to decreased reporter activities in 55.1c mouse and MH1C1 rat hepatoma cells, while the activity of the reporter was increased in FTO-2B rat hepatoma cells. B) Results of additional reporter analyses in 55.1c cells. Cells were cotransfected with the topflash reporter, pRL-CMV, and expression vectors for wild-type (wt) or mutated (S33Y) β-catenin or the respective vector control (pClneo) and incubated with or without PB (1.5 mM) for 24 hours. Topflash-luciferase values were normalized by renilla luciferase activities and represent means ± SD from 3-5 independent experiments. in FTO-2B (55 ± 20) when compared with 55.1c (2.6 ± 0.5) and MH1C1 (6.3 ± 1.8) cells. Subsequently, the activity of the reporter was studied in cells cotransfected with expression vectors for wild-type or mutated (S33Y) β-catenin.
Because wt.-and S33Y-β-catenin mediated significant increases in reporter activity (∼4-to 6-fold, respectively) only in line 55.1c, cells of this line were used for additional analyses. The results demonstrate that PB not only inhibited the basal activity of the topflash reporter but also diminished by about 20% the enhanced activity seen in cells with ectopic expression of β-catenin ( Figure 2B) . Notably, there was no difference in extent of this inhibitory effect between cells cotransfected with expression vectors for the wildtype or the mutant version of the oncoprotein that strongly argues against a selective interference of the barbiturate with gene transcription mediated by β-catenin. β-Catenin and Connexin32: Is There a Connection?
As described previously, ∼80% of tumors from DENinitiated mice promoted by PB harbored β-catenin mutations (see Table 1 ). In addition, we observed by immunohistochemical analysis of Cx32 protein staining that ∼80% of liver tumors in mice of this treatment group showed decreased or negative Cx32-staining (16) . These observations may suggest a causal link between mutation of β-catenin and lack of Cx32 expression in mouse liver tumors. Potentially, mutated β-catenin could negatively regulate the expression of Cx32 mRNA, albeit opposite effects have been observed with respect to Cx43, which appears to be under positive transcriptional control of β-catenin in xenopus (23) . We have tested this hypothesis by in vitro assays using a Cx32-enhancer-regulated luciferase reporter (pCx32-800/-33-Luc; 2). FTO-2B rat hepatoma cells were transfected with the luciferase-reporter and exposed to lithium chloride (15 mM) that inhibits degradation of β-catenin by blocking GSK-3β and thus leads to increased cellular concentrations of the protein. Incubation of FTO-2B cells with lithium chloride led to the expected activation of β-catenin as indicated by an about 2-fold increase in the activity of the β-catenin/TCFresponsive topflash reporter (Figure 3) . In contrast to our FIGURE 3.-Effect of lithium chloride and dexamethasone on the activity of a Connexin32-enhancer driven luciferase reporter (pCx32-800/-33 Luc). FTO-2B rat hepatoma cells were transfected with pCx32-800/-33-Luc or the topflash-reporter and incubated with lithium chloride (15 mM) or dexamethasone (10 µM) for 48 hours. Values from treated cells were normalized for untreated controls and represent means ± SD from 3 independent experiments. TOXICOLOGIC PATHOLOGY hypothesis, however, lithium chloride slightly stimulated rather than inhibited the activity of the Cx32-reporter, even though the enhancing effect was much less than that obtained with dexamethasone, which was used as a positive control because of its well-documented stimulatory activity on the expression of Cx32 in hepatocytes (Figure 3 ). Similar results were obtained with MH1C1 cells (data not shown).
In summary, we have identified 2 important factors relevant for tumor promotion by PB in mouse liver: mutation of β-catenin, observed in 80% of lesions, confers the mutated hepatocytes with a selective growth advantage during the promotional phase. In addition, the fact that promotion by PB requires Cx32 suggests an important role of GJIC during this process. How these two factors are related and whether they do also play a role during promotion with agents of other chemical groups such as the polychlorinated dibenzop-dioxins or the peroxisome proliferators needs to be unraveled. Most importantly, however, it has to be clarified whether the molecular changes relevant during mouse hepatocarcinogenesis are also relevant during development of human HCC.
Analysis of mutations in ras and p53 has demonstrated striking differences in the prevalence of mutations between liver tumors from humans and mice suggesting that the genetic background and other factors that control the clonal expansion of ras and p53 mutated liver cells may differ considerably between species, in particular between humans and mice (eg, see reference 19) . Most human HCCs show abberrant expression and/or intracellular localization of Cx32 (24) and about 20% of human HCCs have activating mutations in the β-catenin gene (for a review see 18). Our present data now suggest that loss of Cx32 function and mutation of β-catenin are both particularly important during the promotional phase of hepatocarcinogenesis in the mouse. In analogy, both proteins may be important during HCC development in humans where induction of liver cell necrosis and regeneration caused by viral infection or alcohol abuse could represent "promoting" stimuli.
